Table 2. Selectivity Profile of OUL35 (3) and Its Analogues against a Panel of ARTs (μM IC_50s) and Activity in the Cell-Based Assay (μM).

	OUL35 (3)a	8b	9b	10c	11c	12d	15d	16d	17d	18e
PARP10	0.330	0.230	2.4	3.64	0.480	0.290	0.140	0.150	0.160	0.400
PARP15	>10f	3.3	1.2	11.0	1.7	2.4	0.400	0.400	0.370	n.t.g
PARP14	23	10	0.630	>100	41	≫10	≫10	≫10	≫10	5.2
TNKS1	>100	>100	n.t.	>100	21	>100	>100	>100	>100	n.t.
TNKS2	>100	>100	>100	>100	6.5	>100	>100	>100	>100	n.t.
PARP1	>100	>100	n.t.	>100	>100	>100	>100	>100	>100	>100
PARP2	>100	>100	>100	27	1.7	38	>100	>100	>100	n.t.
cell-based assayh	1.35	2	n.t.	1.7	1.8	0.59	1.5	1.6	0.95	n.t.

^aReference (93).

^bReference (94).

^cReference (97).

^dReference (96).

^eReference (95).

^fIn PARP15 gain of binding mutant (Y576L), IC₅₀ = 0.295 μM.

^gn.t. = not tested.

^hAbility of the compounds to rescue HeLa cells from PARP10-induced cell death.